Floatz logo

LBH589

Hormone Refractory Prostate Cancer

Novartis PharmaceuticalsPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hormone Refractory Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
at-101
Ascenta Therapeutics
Phase 2BB
RADIUM RA-223
Bayer
Phase 3BB
Docetaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Denosumab
Amgen
Phase 3B

View all 43 →

Same molecule, other indications

LBH589 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
leukemiaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →